Tricida, Inc.

( )
TCDA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.43%178.760.7%$1159.00m
LLYEli Lilly & Co. -0.18%370.421.1%$1137.20m
MRKMerck & Co., Inc. -0.26%109.830.7%$1033.23m
PFEPfizer Inc. 2.02%51.140.9%$991.81m
ABBVAbbVie, Inc. 0.25%161.581.9%$866.05m
BMYBristol-Myers Squibb Co. 0.74%80.871.1%$771.68m
AZNAstraZeneca Plc 0.54%68.341.0%$358.11m
HZNPHorizon Therapeutics Plc 0.59%100.885.4%$309.21m
IDXXIDEXX Laboratories, Inc. 3.12%439.173.9%$229.98m
CTLTCatalent, Inc. 4.21%52.241.9%$213.67m
GSKGSK Plc 1.29%35.040.3%$189.77m
NVSNovartis AG 0.28%89.810.2%$186.33m
NVONovo Nordisk A/S 1.22%126.130.1%$172.82m
ALNYAlnylam Pharmaceuticals, Inc. -0.15%220.258.0%$161.43m
RGENRepligen Corp. 5.22%188.176.7%$134.32m

Company Profile

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.